CIENCIASMEDICASNEWS: FDA approves omidubicel to reduce time to neutrophil recovery and infection in patients with hematologic malignancies | FDA

martes, 18 de abril de 2023

FDA approves omidubicel to reduce time to neutrophil recovery and infection in patients with hematologic malignancies | FDA

FDA approves omidubicel to reduce time to neutrophil recovery and infection in patients with hematologic malignancies | FDA

No hay comentarios:

Publicar un comentario

Suscribirse a: Enviar comentarios (Atom)